Use of Extracorporeal Life Support in Interventions for Pediatric Pulmonary Vein Stenosis

Category	Detail
Condition	Pediatric Pulmonary Vein Stenosis
Key Mechanisms	Veno-arterial extracorporeal life support (VA-ECLS) during cardiac catheterization
Target Population	Pediatric patients with multivessel pulmonary vein stenosis
Care Setting	Pediatric cardiology and intensive care unit

Mortality rates for pediatric pulmonary vein stenosis are 40% for 1-2 vessel disease and 80% for ≥ 3 vessel disease.
Interventional management includes serial cardiac catheterizations with balloon angioplasty and stent placement.
Catastrophic adverse events occur in approximately 12% of multivessel disease cases, with stroke as the predominant AE.
VA-ECLS facilitated successful interventions in high-risk patients without adverse cerebrovascular events.
Patients showed marked improvements in venous obstruction and overall outcomes post-intervention.

Diagnosis of pulmonary vein stenosis confirmed through echocardiography and cardiac catheterization.

Utilization of balloon angioplasty and stent placement for interventional management.
VA-ECLS support during high-risk catheterizations.

Potential for catastrophic adverse events including stroke, pulmonary hemorrhage, and hemodynamic instability.

Pediatric patients with pulmonary vein stenosis and associated conditions.

Patients discharged on a regimen including sirolimus, aspirin, bosentan, and diuretics, with ongoing need for pulmonary vein interventions.

Conduct regular follow-up catheterizations every 3-6 months for ongoing management.
Implement VA-ECLS for patients with significant hemodynamic instability during interventions.